Renovo bet everything on a scar drug — one failed trial killed the company

Renovo Group plc was a UK biopharmaceutical company founded in 2000 as a spin-out from the University of Manchester by Dr Sharon O'Kane. Its sole focus was developing drugs to prevent or reduce scarring — a large unmet need affecting millions of patients each year after surgery, burns, and trauma. The lead candidate was Juvista (avotermin), a recombinant human TGFβ3 protein injected into wound margins at the time of surgery to promote scar-free healing.

Juvista showed promising results in early-stage and mid-stage trials, and the company was listed on the London Stock Exchange's AIM market. By early 2011, Renovo was a single-product company with about 110 employees, a market capitalisation of approximately £240 million, and its only pipeline asset was Juvista in Phase III trials. The entire business was built around this one drug succeeding.

On February 11, 2011, Renovo announced that Juvista had failed its Phase III trial — the drug did not meet its primary efficacy endpoint of improving scar appearance versus placebo. The share price collapsed 75%, falling from about 68 pence to around 17 pence, wiping out approximately £180 million in market value in a single day. Within months, all 110 employees were laid off and the company stopped all pharmaceutical development.

Renovo continued as a shell entity providing financial services and, in August 2014, renamed itself Inspired Capital plc. The Renovo name and its entire drug pipeline were abandoned. The case became a textbook example of the binary risk in biotech investing — a company that had raised tens of millions and employed over a hundred people was destroyed by a single clinical trial failure.